DK193588A - Anvendelser af dopaminagonister - Google Patents

Anvendelser af dopaminagonister

Info

Publication number
DK193588A
DK193588A DK193588A DK193588A DK193588A DK 193588 A DK193588 A DK 193588A DK 193588 A DK193588 A DK 193588A DK 193588 A DK193588 A DK 193588A DK 193588 A DK193588 A DK 193588A
Authority
DK
Denmark
Prior art keywords
dopaminagonists
applications
Prior art date
Application number
DK193588A
Other languages
Danish (da)
English (en)
Other versions
DK193588D0 (da
Inventor
Rudolf Markstein
Jose Palacios
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878708626A external-priority patent/GB8708626D0/en
Priority claimed from GB878708898A external-priority patent/GB8708898D0/en
Priority claimed from GB878710062A external-priority patent/GB8710062D0/en
Priority claimed from GB878720366A external-priority patent/GB8720366D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of DK193588D0 publication Critical patent/DK193588D0/da
Publication of DK193588A publication Critical patent/DK193588A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK193588A 1987-04-10 1988-04-08 Anvendelser af dopaminagonister DK193588A (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878708626A GB8708626D0 (en) 1987-04-10 1987-04-10 Indolophenanthridines
GB878708898A GB8708898D0 (en) 1987-04-14 1987-04-14 Indolophenanthridines
GB878710062A GB8710062D0 (en) 1987-04-28 1987-04-28 Indolophenanthridines
GB878720366A GB8720366D0 (en) 1987-08-28 1987-08-28 Dopamine d1 receptor agonists

Publications (2)

Publication Number Publication Date
DK193588D0 DK193588D0 (da) 1988-04-08
DK193588A true DK193588A (da) 1988-10-11

Family

ID=27449909

Family Applications (1)

Application Number Title Priority Date Filing Date
DK193588A DK193588A (da) 1987-04-10 1988-04-08 Anvendelser af dopaminagonister

Country Status (11)

Country Link
US (1) US4855306A (it)
JP (1) JPS63258819A (it)
KR (1) KR880012227A (it)
AU (1) AU1440088A (it)
DE (1) DE3811274A1 (it)
DK (1) DK193588A (it)
FR (1) FR2613623A1 (it)
GB (1) GB2205495A (it)
IT (1) IT1219906B (it)
NL (1) NL8800823A (it)
SE (1) SE8801275A0 (it)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
JP4545584B2 (ja) * 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
DE10312809A1 (de) * 2003-03-21 2004-09-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern
US20040266794A1 (en) * 2003-03-21 2004-12-30 Boehringer Ingelheim International Gmbh Pramipexole for the reduction of excessive food intake for children
PT2316456T (pt) * 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
WO2004103262A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
BRPI0506829A (pt) * 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
US20080306019A1 (en) * 2005-05-03 2008-12-11 Booze Rosemarie M Dopamine Receptor Agonists in the Treatment and Prevention of Hiv-Induced Dementia
DK2135603T3 (da) 2005-11-22 2013-03-25 Orexigen Therapeutics Inc Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2750903C (en) * 2009-08-27 2015-08-11 Daikin Industries, Ltd. Processing additive, molding composition, masterbatch of processing additive and molding article
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
EP2858640B1 (en) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3402392A1 (de) * 1984-01-25 1985-08-01 Sandoz-Patent-GmbH, 7850 Lörrach Neue ergolinderivate, deren herstellung und deren verwendung

Also Published As

Publication number Publication date
SE8801275L (sv) 1988-10-19
US4855306A (en) 1989-08-08
KR880012227A (ko) 1988-11-26
JPS63258819A (ja) 1988-10-26
NL8800823A (nl) 1988-11-01
FR2613623A1 (fr) 1988-10-14
GB2205495A (en) 1988-12-14
AU1440088A (en) 1988-10-13
IT8847814A0 (it) 1988-04-05
GB8808125D0 (en) 1988-05-11
DE3811274A1 (de) 1988-10-27
SE8801275D0 (sv) 1988-04-08
IT1219906B (it) 1990-05-24
DK193588D0 (da) 1988-04-08
SE8801275A0 (sv) 1988-10-19

Similar Documents

Publication Publication Date Title
DK193588D0 (da) Anvendelser af dopaminagonister
DK208188D0 (da) Anvendelse af 17-ketosteroider
DK450189A (da) Strimmel af sammenfoejede soem
DK363887D0 (da) Anvendelse af bromcruptin
DK348385A (da) Anvendelse af cyclosporiner
DK662687D0 (da) Anvendelse af tricycliske carbazoloner
DK25389A (da) Tolkning af elektriske diagrafier
DK549688A (da) Fremstilling af peptider
DK185988D0 (da) Anvendelse af antigen
DK360484D0 (da) Modifikation af soja-isolat
DK38593A (da) Alkoxymethylethere af glyceroler
DK102389A (da) Anvendelse af interleukin
DK119688D0 (da) 23-oxo- (-keto-) og 23-imino-derivater af mono- og diepoxy-ll-f28249-forbindelser
DK316589D0 (da) Substituerede azacyclohexylderivater af rifamyciner
DK104489D0 (da) Anvendelse af triazolderivater
DK562289A (da) Anvendelse af somatostatiner
DK293787D0 (da) Ekspression af en amyloglucosidase
DK426089D0 (da) Omestring af phospholipider
DK541487A (da) Sammenfoejning af materialer
DK251788D0 (da) Stabile creatinamidinohydrolasemutanter
DK105089A (da) Fremstilling af bis(amin-holdige)benzendioler
DK487289D0 (da) Omestring af phospholipider
DK153045C (da) Sammenkobling af fortrinsvis langstrakte elementer
DK621088D0 (da) Theemballage af theposetypen
DK531987D0 (da) Oprensning af antistoffer

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment